🇺🇸 FDA
Drug

alirocumab

Brand: PRALUENT

approved

Quick answer

alirocumab (PRALUENT), is a pharmaceutical active ingredient, associated with REGENERON PHARMACEUTICALS, INC., with approved status in the US.

Key facts

INN
alirocumab
Brand
PRALUENT
Route
INJECTION
Formulation
INJECTABLE
Originator
REGENERON PHARMACEUTICALS, INC.

Related patents

patent

US 11904017

Methods for reducing or eliminating the need for lipoprotein apheresis in patien

Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10772956

Methods for reducing or eliminating the need for lipoprotein apheresis in patien

Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

Frequently asked questions

What is alirocumab?

alirocumab (PRALUENT), is a pharmaceutical active ingredient, associated with REGENERON PHARMACEUTICALS, INC., with approved status in the US.

What is the brand name for alirocumab?

PRALUENT is a marketed brand name for alirocumab. Check FDA Drugs@FDA for the current US label holder.